OPXA is on my watchlist for 3 forward event plays this year, specifically as follows;
1. I expect news regarding a progress payment from Novartis under OPXA's deal with Novartis for islet stem cell technology (diabetes potential). When it occurs, I expect will provide a temporary +33% impact to OPXA's PPS. The deal with Novartis has been valued by OPXA in prior PR and SEC filings at $50mm.
2. I expect OPXA to announce progress on FDA filing of its Tovaxin Phase IIb in the first half of this year. When it occurs, I expect this forward event play to provide a temporary +300% impact to OPXA's PPS, and then re-base OPXA higher by 75%.
3. I expect OPXA to announce progress on a partnership to commercialize Tovaxin in 2010. When it occurs, I expect this to provide significant temporary impact to OPXA's PPS of +100% or higher (depending on how much rebase is observed from Tovaxin's FDA progress).
OPXA is a Naz big board play. Tovaxin is a promising therapy for Multiple Sclerosis- a $9b global market.
OPXA's recent chart and insider buying signal to me that this will be an exciting quarter.
Tovaxin's first FDA trial yielded statistically significant efficacy and safety data.
OPXA entered 2010 with a strong cash position to fund operations and recently completed a direct placement secondary offering to raise cash for Tovaxin's continued development. I anticipate no further dilution until substantial news breaks.
Best wishes to all in 2010
tnzalu
AI
Market Data 
Markets 
